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Background
Gonarthrosis is the most common cause of pain and
disability in middle-aged and elderly people [1,2]. The
lack of long-lasting effective treatments for repairing
degenerated articular cartilage has spurred research into
novel cell-based therapies aiming at reducing pain,
slowing the degeneration of cartilage and, ultimately,
reverting the natural history of osteoarthritis (OA) [3].
Herein we report the development of a mesenchymal
stromal cell (MSC)-based therapy, from conception up
to completion of a Phase I/IIa prospective, open-label,
single-dose, single-arm clinical trial.
Materials and methods
All animal care and experimental procedures adhered to
the recommendations of local, national, and European
laws and were approved by the appropriate Ethical
Committees on Human and Animal Experimentation.
A GMP-compliant bioprocess was designed for the
production of the investigational cell-based medicinal
product. Characterisation of MSC adhered to the mini-
mal criteria established by the International Society for
Cellular Therapy [4].
For the clinical study (EUDRA-CT: 2009-016449-24;
ClinicalTrials.gov Identifier: NCT01227694), fifteen
patients with grade II/ III OA (Kellgren&Lawrence score
[5]) and chronic pain were treated intraarticularly with
clinical grade MSC and were followed up to 12 months.
Primary endpoints were safety and tolerability. Addition-
ally, therapeutic efficacy was measured by the Visual
Analogue Scale (VAS) for daily activity and on exertion
[6], Health Assessment Questionnaire (HAQ) [7], the
SF-36 questionnaire [8], the Western Ontario and
McMaster Universities Arthritis (WOMAC) and Lequesne
functional indexes [9]. Cartilage integrity was assessed by
magnetic resonance imaging (MRI) and T2 relaxation
time mapping [10,11].
Results and discussion
Along the development programme, Good Scientific Prac-
tice (GxP) quality standards were implemented gradually
in our laboratory (Figure 1) [12].
The preclinical package included a proof-of-principle
study in a large animal model of chronic OA and three
regulatory preclinical studies in murine animal models
(Table 1 Figure 1). The intra-articular injection of auto-
logous MSC was safe, as judged by the lack of local or
systemic adverse effects and evidence of regeneration of
articular cartilage and meniscus was found in specific
macroscopic and histological parameters [13]. Three
further regulatory preclinical studies were performed in
murine animal models in order to 1) assess subchronic
toxicology, 2) analyse the biodistribution of human MSC,
and 3) investigate dose:response relationship. Our results
highlighted the safety of MSC either administered intra-
articularly (up to 6x105MSC/knee in rats) or intrave-
nously (IV, 1.3x107 MSC/kg in mice) and the persistence
of IV-infused MSC in liver, kidney and spleen, at 3
months post-administration. No tumours were detected
in any of the animals during the observation period. IV
transplanted hMSC were principally found in the liver,
kidneys and spleen of immunocompromised mice. The
lungs, in spite of receiving a considerable number of cells
immediately after administration, did not appear to be a
welcoming environment adequate for MSC survival, thus
confirming other author’s observations [14].* Correspondence: jvives@bst.cat
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Previous data in large translational animal models [15],
and investigations on the role of MSC in cartilage [16,17]
and bone [18] regeneration, provided further support with
respect to the safety and regenerative qualities of MSC.
For the clinical testing in humans, the drug product
consisted in 40.9x106 ± 0.4x106 viable MSC in 10.0 ±
0.3 mL of saline solution. The phenotypic characteristics
of the human MSC used in the study were 99.7% ±
0.2% CD45-CD105+, 99.0% ± 0.6% CD31-CD73+, 99.9 ±
0.3% CD90 and 15.5% ± 14.8 HLA-DR+. The combina-
tion of differentiation assays, growth profiles, morphol-
ogy assessment and cytometric phenotype confirmed
the MSC nature of the cells used in our studies. MSC
suspensions tested negative for bacteria, mycoplasma
and endotoxin before infusion into humans. The
analgesic effect of the intra-articular infusion of MSC
Figure 1 Schematic representation of the product development package. eGFP=enhanced Green Fluorescent Protein; GCP=Good Clinical
Practice; GLP=Good Laboratory Practice; GMP=Good Manufacturing practice; MSC=Mesenchymal Stromal Cell.
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was remarkable, with all patients showing some degree
of improvement in daily life physical activity and on
exertion at month 12. Indeed all WOMAC, Lequesne
and VAS indexes decreased in a similar manner over
time, the most significant changes being observed at
6 and 12 months after treatment. A significant
improvement was observed at 12 months in the vitality
scale and at 3 months in the global health scale. HAQ
decreased significantly from 0.38 at the basal visit to
0.2 at 12 months (p<0.05), thus indicating a global
improvement of the perceived health status.
With respect to cartilage integrity, T2 values decreased
significantly over time in all patients. These results may
be indicative of regeneration of the articular cartilage in
all patients at 1-year post-treatment. The fact that no
pathological values were observed at 12 months in prior
healthy areas highlighted the preventive effect of MSC on
further degeneration.
Conclusions
We successfully designed and executed a reproducible
GMP-compliant bioprocess for the manufacture of cell-
based therapeutics. The clinical procedure involved a
minimally invasive intervention, which was feasible and
safe, resulting in pain relief and preventing further degen-
eration of articular cartilage.
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4x105 hMSC;
tail-vein injection











X X Analysis of protooncogen expression levels, hTERT activity, senescense, G-banding
karyotype, and CGH arrays on clinical grade hMSC
In vitro assays N/A
X X Adult Stem Cell Therapy for Repairing Articular Cartilage in Gonarthrosis (EUDRA-
CT: 2009-016449-24; ClinicalTrials.gov Identifier: NCT01227694)




GxP compliance of non-clinical and clinical studies, and for the production of batches of MSC are also indicated. GCP=Good Clinical Practice; GLP=Good
Laboratory Practice; GMP=Good Manufacturing practice; MIA=monoiodoacetate; MSC=Mesenchymal Stromal Cell; OA=osteoarthritis; N/A=Not Applicable;
NIH=National Institutes of Health; NRG=NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ.
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